Birmingham, ALNCT06079671Now EnrollingIRB Ready

Cervical Cancer Clinical Trial in Birmingham, AL

Access cutting-edge cervical cancer treatment through this phase 3 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access cervical cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cervical cancer treatment provided free

Apply for This Birmingham Location

Check if you qualify for this cervical cancer clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Cervical Cancer Study in Birmingham

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

For inclusion in the study, patients should fulfill the following criteria:
Aged at least 15 years at the time of screening. Note: Participants \< 18 years of age: physical changes should be aligned with Tanner Stage III.
Body weight \> 35 kg.
Histologically documented FIGO 2018 Stage IIIA to IVA cervical adenocarcinoma, cervical squamous carcinoma, or cervical adenosquamous carcinoma, with no evidence of metastatic disease.
Initial staging procedures performed no more than 56 days prior to the first dose of CCRT.
Provision of FFPE tumor sample to assess the PD-L1 expression.
Must not have progressed following CCRT, participants with persistent disease after definitive CCRT must not be amenable to other available therapies with curative intent.
WHO/ECOG performance status of 0 or 1; duration of life expectancy of ≥ 12 weeks.
Adequate organ and bone marrow function.
Capable of providing signed informed consent.

Exclusion Criteria

Patients should not enter the study if any of the following exclusion criteria are fulfilled:
Diagnosis of small cell (neuroendocrine) or mucinous adenocarcinoma of cervical cancer.
Evidence of metastatic disease.
Intent to administer a fertility-sparing treatment regimen.
History of organ transplant or allogenic stem cell transplant.
History of active primary immunodeficiency or active or prior documented autoimmune or inflammatory disorders.
Uncontrolled intercurrent illness.
History of another primary malignancy except for a) Malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention; b) Adequately treated nonmelanoma skin cancer or lentigo maligna, or carcinoma in situ without evidence of disease.
Unresolved toxicities from previous CCRT except for irreversible toxicity that is not reasonably expected to be exacerbated.
Prior history or presence of vesicovaginal, colovaginal, or rectovaginal fistula.
History of anaphylaxis to any biologic therapy or vaccine.
Current or prior use of immunosuppressive medication within 14 days before the first dose of the study intervention is excluded. The following are exceptions to this criterion: a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular injection); b) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication or chemotherapy premedication) or a single dose for palliative purpose (eg, pain control); c) Physiologic doses of oral corticosteroids, ie, not exceeding 10 mg/day of prednisone (or equivalent) in the preceding 14 days.
Patients who have undergone a previous hysterectomy, including a supracervical hysterectomy, or will have a hysterectomy as part of their initial cervical cancer therapy.
Any prior (besides prior CCRT) or concurrent treatment for cervical cancer.
Major surgical procedures within 4 weeks prior to the first dose of the study intervention or still recovering from prior surgery.
Exposure to immune mediated therapy prior to the study for any indication.
Receipt of live attenuated vaccine within 30 days prior to the first dose of the study intervention.
Participants with a known allergy or hypersensitivity to the study intervention, or any excipients of the study intervention.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT06079671) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cervical Cancer Treatment Options in Birmingham, AL

If you're searching for cervical cancer treatment options in Birmingham, AL, this clinical trial (NCT06079671) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced cervical cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cervical cancer clinical trials near you to find additional studies recruiting in your area.

More Cervical Cancer Trials in Birmingham, AL

See all cervical cancer clinical trials recruiting in Birmingham — not just this study.

Browse Cervical Cancer Trials in Birmingham →

Browse More Trials by Condition

Cervical Cancer TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL